Clinical trials: Dexamethasone Administration
Multiple Myeloma
Selinexor Treatment of Refractory Myeloma
This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with penta-refractory MM (Parts 1 and 2) or quad refractory MM…
- Trial name
- STORM (NCT02336815)
- Testing
- Selinexor, Dexamethasone
- Where
- 61 sites in United States, Austria and 4 more
- Volunteers
- 202 people
- Sponsor
- Karyopharm Therapeutics Inc
Otitis Externa
A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa
The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par Pharmaceutical Companies, Inc.) to the already-marketed…
- Trial name
- NCT01910155
- Testing
- Ciprofloxacin/Dexamethasone, Ciprodex (R)
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 455 people
- Sponsor
- Par Pharmaceutical, Inc.
Blepharitis
Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-502 compared to AzaSite® alone, Dexamethasone alone, and vehicle in the treatment of subjects with Non-bacterial Blepharitis.
- Trial name
- DOUBle (NCT01408082)
- Testing
- ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined), Azasite, Dexamethasone
- Where
- 45 sites in United States
- Volunteers
- 917 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Active, Symptomatic Blepharitis
Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.
- Trial name
- ISV-305 (NCT01543490)
- Testing
- ISV-305, Vehicle
- Where
- United States
- Volunteers
- 558 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Acute Otitis Externa
FST-201 In The Treatment of Acute Otitis Externa
The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa.
- Trial name
- NCT00945802
- Testing
- FST-201 (dexamethasone 0.1%) Otic Suspension, ciprofloxacin 0.3%, dexamethasone 0.1%
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Shire
Multiple Myeloma
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.
- Trial name
- NIMBUS (NCT01311687)
- Testing
- pomalidomide, Dexamethasone
- Where
- 94 sites in United States, Australia and 14 more
- Volunteers
- 455 people
- Sponsor
- Celgene
Multiple Myeloma
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in…
- Trial name
- UPFRONT (NCT00507416)
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- 235 sites in United States, Puerto Rico
- Volunteers
- 502 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer, Nausea
Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy
The purpose of the study is verify the capability of a standardized Ginger (Zingiber officinale) extract to manage nausea in cancer patients receiving highly emetogenic treatments and standard anti-emetogenic therapy.
- Conditions
- Cancer, Nausea, Vomiting
- Trial name
- NCT01887314
- Testing
- Standardized Ginger extract
- Where
- 6 sites in Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Helsinn Healthcare SA
Cataract
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated with Cataract Surgery
- Trial name
- NCT05550363
- Testing
- Dexycu
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Inflammation, Cataract
A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery
This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.
- Trial name
- NCT06497699
- Testing
- Dexycu
- Where
- 2 sites in China
- Volunteers
- 263 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Inflammation, Cataract
Study of Dexycu in Treating Intraocular Inflammation
This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of…
- Trial name
- NCT06429306
- Testing
- Dexycu
- Where
- China
- Volunteers
- 285 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Macular Edema
Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)
This study will assess the safety and efficacy of 700 μg dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in patients with macular edema in a 6 month double-blind period versus sham followed by…
- Trial name
- NCT01660802
- Testing
- 700 μg Dexamethasone
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Allergan
Inflammation Eye
A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of two dose levels of dexamethasone ophthalmic suspension eye drops to determine if the drops decrease…
- Trial name
- NCT03687931
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- iDrop, Inc.
Ataxia Telangiectasia, Genetic Syndrome
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
Primary Objective To monitor and evaluate the long-term safety and tolerability of EDS-EP in AT patients. Secondary Objective To evaluate the long-term effect of EDS-EP on health-related Quality of Life (QoL; EQ-5D-5L scale).
- Trial name
- OLE-IEDAT (NCT03563053)
- Testing
- EryDex System
- Where
- 17 sites in United States, Australia and 9 more
- Volunteers
- 104 people
- Sponsor
- Quince Therapeutics S.p.A.
Diabetic Macular Edema
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide [FA] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092…
- Trial name
- BETTIS-1 (NCT06536491)
- Testing
- EC-104 high dose, EC-104 low dose, Dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Eclipse Life Sciences, Inc.
Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma
The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.
- Conditions
- Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular
- Trial name
- NCT00060684
- Testing
- Pixantrone (BBR 2778), fludarabine, dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- CTI BioPharma
Multiple Myeloma
Expanded Access Treatment Protocol CA204-143
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S.
- Trial name
- NCT02368301
- Testing
- Elotuzumab in combination with Lenalidomide and Dexamethasone
- Sponsor
- Bristol-Myers Squibb
Postoperative Ileus
Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)
This study is being conducted to determine whether Dexamethasone-Allantoin-Metronidazole (DAM) Solution can accelerate recovery of gastrointestinal function following abdominal operation when compared with a placebo.
- Trial name
- NCT01863407
- Testing
- DAM, Normal Saline
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Beijing Bozhiyin T&S Co., Ltd.
Relapse/Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with…
- Trial name
- MARCH (NCT03944057)
- Testing
- ATG-010
- Where
- 17 sites in China
- Volunteers
- 82 people
- Sponsor
- Antengene Corporation
Multiple Myeloma
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory…
- Trial name
- NCT00833833
- Testing
- Pomalidomide, Dexamethasone, Aspirin
- Where
- 19 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Celgene Corporation